2026 年 7 月，成都施贝康生物医药科技有限公司受邀参加由美国心脏协会（AHA）主办的BCVS科学会议，以及由美国心血管研究卓越学会（ACRE）协办的第八届亚洲心血管论坛（ACS）。与来自全球的心血管领域专家学者、临床医生及产业界代表展开学术交流，并在ACS研讨会上发表主题演讲，分享公司核心管线与AI药物平台研发进展。亮相国际学术平台，深化全球学术交流协作 BCVS 2026 科学会议：由美国心脏协会（AHA）主办，由AHA主席Manesh R. Patel教授牵头组织，是全球基础心血管转化医学领域极具影响力的学术盛会，汇聚全球顶尖科研、临床及产业资源，引领心血管基础研究、技术转化及临床应用的前沿发展方向。第八届亚洲心血管论坛：由美国心血管研究卓越学会（ACRE）协办，聚焦心血管疾病前沿科研成果共享与产学研协同创新，搭建了衔接北美与亚洲、贯通全球心血管领域的专业化交流合作平台。分享管线研发进展，展示AI驱动研发体系在ACS研讨会上，施贝康市场医学部负责人发表题为《Shibeikang's Current R&D Pipeline: Key Candidates and Development Status》的主题演讲，系统介绍了公司的研发布局与核心管线研发进展。重点分享了新一代祛痰药物SBK001，抗血小板药物sbk002（吡康格雷），第三代抗组胺药物SBK007的最新研发进展，阐述了核心管线针对性解决临床未满足需求的创新价值，以及在安全性、有效性方面的差异化优势。同时，施贝康展示了AI代谢差异化研究平台的实际应用成果。依托该智能研发体系，公司建立了标准化的全流程创新研发链路，覆盖靶点发现、临床前研究、工艺优化至临床转化全过程，为创新药物的精准、高效研发提供系统化技术支撑。本次报告内容获得与会专家的高度关注与认可。成都施贝康生物医药科技有限公司，成立于2015年，是一家立足中国，面向全球，专注于新药差异化创新的研发性企业。施贝康秉承“施予众生、倍佑安康”的使命，坚持“以‘人’为本，革新为主，创新至上”的价值观。以临床需求为导向，坚持创新驱动发展，重点聚焦心脑血管、呼吸系统等疾病治疗领域，致力于成为全球一流的新药差异化创新的领导者，研发更好的新药，施予众生，加倍呵护人类健康。详情请访问公司网站： https://www.sbkswyy.cn/ Shibeikang Showcases Core Pipeline and AI-Powered Drug Discovery Platform at BCVS 2026 and Asian Cardiovascular Symposium (ACS) In July 2026, Chengdu Shibeikang Biomedical Technology Co., Ltd. participated in the Basic Cardiovascular Sciences (BCVS) Scientific Sessions organized by the American Heart Association (AHA), as well as the 8th Annual Asian Cardiovascular Symposium (ACS), co-organized by the Academy of Cardiovascular Research Excellence (ACRE). The company engaged in academic exchanges with leading cardiovascular experts, clinicians, and industry representatives from around the world, and delivered a keynote address at the ACS Symposium to share the progress of its core pipeline and AI-powered drug discovery platform. Advancing Global Collaboration Through Leading Cardiovascular Platforms BCVS 2026 Scientific Sessions: Organized by the American Heart Association (AHA) under the leadership of AHA President Professor Manesh R. Patel, the event serves as a leading global forum for basic and translational cardiovascular science. It brings together experts from research, clinical practice, and industry to advance innovation in cardiovascular research, translational medicine, and clinical applications. 8th Annual Asian Cardiovascular Symposium: Co-organized by the Academy of Cardiovascular Research Excellence (ACRE), the symposium focuses on the latest advances in cardiovascular research and promotes collaboration among academia, research institutions, and industry. The event provides a professional platform connecting North America and Asia while facilitating global exchange and innovation in cardiovascular science. Sharing Pipeline Progress and Highlighting AI-Enabled R&D Capabilities At the ACS Symposium, the Head of the Medical Marketing at Shibeikang delivered a keynote address titled Shibeikang's Current R&D Pipeline: Key Candidates and Development Status, providing a systematic overview of the company’s R&D landscape and the progress of its core pipeline. The presentation highlighted recent development updates for SBK001, a next-generation expectorant; sbk002 (Becondogrel), an antiplatelet agent; and SBK007, a third-generation antihistamine. It also showcased the potential value of these programs in addressing unmet clinical needs, supported by their differentiated safety and efficacy profiles. Shibeikang also shared practical achievements from its AI-powered metabolically differentiated R&D platform. Leveraging this intelligent R&D system, the company has developed a standardized, end-to-end innovation workflow covering target discovery, preclinical research, process optimization, and clinical translation. This platform provides integrated technical support to enable more precise and efficient development of innovative therapies. The presentation attracted significant attention and received positive feedback from participating experts. Founded in 2015, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world, dedicated to differentiated drug innovation. Guided by our mission of "Improving Public Health with Innovative Medicines and Caring Expertise", SBK is committed to the corporate values of "'People-centered', Driven by Change, Innovation at the Core". Guided by clinical needs, we pursue an innovation-driven strategy with a focus on differentiated R&D. Specializing in cardiovascular, cerebrovascular, and respiratory therapies, we are dedicated to become a global leader in the differentiated innovation of new drugs, to develop better medicines, broaden global access, and elevate human health through unwavering commitment. For further details, please visit the official SBK website： https://www.sbkswyy.cn/

2026-06-26

·施贝康生物

施贝康SBK007研究成果重磅亮相2026欧洲变态反应学大会

2026 年 6 月 12-15日，由成都施贝康生物医药科技有限公司自主研发的新一代抗过敏药物SBK007 的临床前研究成果，在 2026 年欧洲变态反应与临床免疫学会大会（EAACI Congress 2026）上完成现场报告与学术交流。本次报告题目为《SBK007: A Novel Oral H1 Antihistamine with Rapid Onset (30min): Preclinical Pharmacodynamics in Acute Urticaria》。 EAACI 2026：全球过敏免疫领域权威学术盛会欧洲变态反应与临床免疫学会（EAACI）是全球过敏与临床免疫领域最具权威性的专业学术组织，其年度大会是该领域规格最高、学术影响力最广的国际盛会。本届大会以 “Vision Zero: A Future Free from Allergy and Asthma Burden” 为主题，由 EAACI 现任学会主席 María José Torres 教授与大会主席 André Moreira 教授共同筹办，吸引了全球百余国家超 2 万名领域专家齐聚参会，是过敏疾病诊疗与新药研发前沿成果的核心学术交流平台。 SBK007：快速起效抗组胺新药，直击急性荨麻疹临床痛点 SBK007是施贝康自主开发的新一代口服 H1 抗组胺药物，临床前数据显示，其起效迅速（30分钟），药效呈明显剂量依赖性，且显著优于对照药物，可精准满足急性荨麻疹患者对 “即时症状控制” 的核心治疗需求，有望为重症、急诊患者提供更便捷高效的口服治疗新选择。本次大会披露的研究数据，为SBK007 推进临床转化提供了充分的科学依据。成都施贝康生物医药科技有限公司，成立于2015年，是一家立足中国，面向全球，专注于新药差异化创新的研发性企业。施贝康秉承“施予众生、倍佑安康”的使命，坚持“以‘人’为本，革新为主，创新至上”的价值观。以临床需求为导向，坚持创新驱动发展，重点聚焦心脑血管、呼吸系统等疾病治疗领域，致力于成为全球一流的新药差异化创新的领导者，研发更好的新药，施予众生，加倍呵护人类健康。详情请访问公司网站： https://www.sbkswyy.cn/ Groundbreaking Study Findings on SBK007 Presented at EAACI Congress 2026 From 12 to 15 June 2026, the preclinical study findings of SBK007, a novel next‑generation anti‑allergic agent independently developed by Chengdu Shibeikang Biomedical Technology Co., Ltd., were presented and discussed at the European Academy of Allergy and Clinical Immunology Congress 2026 (EAACI Congress 2026). The presentation was titled SBK007: A Novel Oral H1 Antihistamine with Rapid Onset (30min): Preclinical Pharmacodynamics in Acute Urticaria. EAACI 2026: A Leading Global Conference in Allergy and Immunology The European Academy of Allergology and Clinical Immunology (EAACI) stands as the leading professional organization globally in the fields of allergy and clinical immunology. Its annual congress represents the most prestigious and academically influential international event in this domain. Under the theme of Vision Zero: A Future Free from Allergy and Asthma Burden, EAACI Congress 2026 was jointly organized by Prof. María José Torres, current President of EAACI, and Prof. André Moreira, Chair of the Congress. The event attracted over 20,000 experts from more than 100 countries worldwide, serving as a premier platform for exchanging cutting-edge advancements in allergy diagnosis, treatment, and pharmaceutical development. SBK007: A Fast-Acting Novel Antihistamine Addressing Critical Unmet Needs in Acute Urticaria SBK007 is an orally administered H1 antihistamine independently developed by Shibeikang Biomedical. Preclinical studies indicate that it exhibits rapid onset of action, achieving therapeutic effects within just 30 minutes. Its efficacy demonstrates clear dose-dependency and significantly outperforms existing comparator drugs. Consequently, SBK007 is well-positioned to meet the urgent need for immediate symptom control among patients suffering from acute urticaria, potentially offering a convenient and efficient oral therapeutic alternative—particularly for severe or emergency cases. The data presented at the Congress provide robust scientific justification for advancing SBK007 into subsequent phases of clinical development. Founded in 2015, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world, dedicated to differentiated drug innovation. Guided by our mission of "Improving Public Health with Innovative Medicines and Caring Expertise", SBK is committed to the corporate values of "'People-centered', Driven by Change, Innovation at the Core". Guided by clinical needs, we pursue an innovation-driven strategy with a focus on differentiated R&D. Specializing in cardiovascular, cerebrovascular, and respiratory therapies, we are dedicated to become a global leader in the differentiated innovation of new drugs, to develop better medicines, broaden global access, and elevate human health through unwavering commitment. For further details, please visit the official SBK website： https://www.sbkswyy.cn/

临床研究

2026-03-13

·施贝康生物

施贝康SBK007研究成果Abstract将亮相国际会议（EAACI Congress 2026）

2026年3月12日，由成都施贝康生物医药科技有限公司（下称“施贝康”）自主研发的全新一代抗过敏药物SBK007最新研究成果，成功入选2026年欧洲变态反应与临床免疫学会大会（ EAACI Congress 2026）。研究题目为《SBK007: A Novel Oral H1 Antihistamine with Rapid Onset (30min): Preclinical Pharmacodynamics in Acute Urticaria》，相关内容将在大会期间展示并进行演讲汇报，与参会专家开展面对面学术交流。 EAACI 2026 全球过敏免疫领域权威学术盛会欧洲变态反应与临床免疫学会（EAACI）是全球过敏与临床免疫领域最具权威性的专业学术组织，其年度大会是该领域规格最高、学术影响力最广的国际盛会，汇聚全球顶尖专家学者、临床医师与医药研发人员，聚焦过敏性疾病诊疗与新药研发前沿进展。大会摘要采用严格的同行评审机制，仅收录具备高学术价值与创新性的研究成果，是全球过敏领域核心的学术交流与成果展示平台。 SBK007 直击急性荨麻疹临床痛点，实现即时症状控制急性荨麻疹作为临床高发过敏性疾病，以快速缓解瘙痒、风团症状为核心治疗目标。当前抗组胺药普遍存在起效迟缓，药效不足的局限，无法满足急诊、重症患者 “即时症状控制” 的核心治疗需求， SBK007 系统性完成了针对急性荨麻疹核心病理环节的临床前药效学评价，凭借快速起效、药效强劲的核心优势，有望降低临床给药剂量、提升用药安全性，为急性荨麻疹尤其是重症、急诊患者提供更便捷高效的口服治疗新选择，为临床转化提供了严谨的科学依据。成都施贝康生物医药科技有限公司，成立于2015年，是一家立足中国，面向全球，专注于新药差异化创新的研发性企业。施贝康秉承“施予众生、倍佑安康”的使命，坚持“以‘人’为本，革新为主，创新至上”的价值观。以临床需求为导向，坚持创新驱动发展，重点聚焦心脑血管、呼吸系统等疾病治疗领域，致力于成为全球一流的新药差异化创新的领导者，研发更好的新药，施予众生，加倍呵护人类健康。详情请访问公司网站： https://www.sbkswyy.cn/ SBK’s SBK007 Research Abstract Accepted for Presentation（EAACI Congress 2026） On March 12, 2026, the latest research findings on SBK007, a next-generation anti-allergy drug independently developed by Chengdu Shibeikang Biomedical Technology Co., Ltd. (“SBK”), were accepted for presentation at the EAACI Congress 2026. The study, titled SBK007: A Novel Oral H1 Antihistamine with Rapid Onset (30 min): Preclinical Pharmacodynamics in Acute Urticaria, will be presented at the congress, providing an opportunity for in-person academic exchange with international experts. EAACI 2026: A Leading Global Conference in Allergy and Immunology Organized by the European Academy of Allergy and Clinical Immunology, the EAACI Annual Congress is one of the most influential international events in the field of allergy and clinical immunology. The meeting brings together leading researchers, clinicians, and pharmaceutical scientists from around the world to discuss the latest advances in allergy diagnosis, treatment, and drug development. Abstracts accepted for presentation undergo a rigorous peer-review process, with selection based on scientific quality, innovation, and relevance. As a result, the congress serves as an important global platform for sharing research findings and advancing the field of allergy science. SBK007: Targeting Rapid Symptom Relief in Acute Urticaria Acute urticaria is a common allergic condition in which rapid relief of itching and wheal formation is a primary treatment goal. Many currently available antihistamines have limitations, including delayed onset or suboptimal efficacy, which may not fully address the need for immediate symptom control in severe or urgent cases. SBK007 has undergone systematic preclinical pharmacodynamic evaluation targeting key pathological mechanisms involved in acute urticaria. With a rapid onset of action and strong antihistamine activity, SBK007 has the potential to reduce dosing requirements, improve safety, and provide a more convenient and effective oral treatment option for patients with acute urticaria—particularly in severe or acute episodes. These findings provide important scientific support for future clinical development and translation. Founded in 2015, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world, dedicated to differentiated drug innovation. Guided by our mission of "Improving Public Health with Innovative Medicines and Caring Expertise", SBK is committed to the corporate values of "'People-centered', Driven by Change, Innovation at the Core". Guided by clinical needs, we pursue an innovation-driven strategy with a focus on differentiated R&D. Specializing in cardiovascular, cerebrovascular, and respiratory therapies, we are dedicated to become a global leader in the differentiated innovation of new drugs, to develop better medicines, broaden global access, and elevate human health through unwavering commitment. For further details, please visit the official SBK website： https://www.sbkswyy.cn/

临床研究

100 项与 SBK007 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
常年性变应性鼻炎	临床2期	中国	成都施贝康生物医药科技有限公司	2026-03-03
季节性过敏性鼻炎	临床2期	中国	成都施贝康生物医药科技有限公司	2026-03-03
急性荨麻疹	临床1期	中国	成都施贝康生物医药科技有限公司	2024-08-21